Zynk | $5,000,000 | (Nov 5, 2025)
Downstream | $8,000,000 | (Nov 5, 2025)
Ruli | $6,000,000 | (Nov 5, 2025)
Deep Apple Therapeutics
United States
- San Francisco Bay Area
- 18/12/2023
- Series A
- $52,000,000
In a vast, unexplored virtual chemical space, Deep Apple Therapeutics moves with unprecedented speed to discover novel small molecules for high-value targets. Deep Apple combines ensemble cryo-EM to explore receptor conformations; deep learning; and the docking of multi-billion compound libraries generated using the company's proprietary Orchard.ai™ algorithm. Deep Apple's deep learning discovery engine is built upon founder expertise in computational modeling, protein and target structure determination, large-scale molecular docking, and the elucidation of protein dynamics and conformational transitions. This structure-based, machine-learning driven drug design approach enables the company to rapidly advance novel candidates addressing well-validated targets in inflammatory, metabolic, and endocrine diseases. For more information, visit deepappletx.com.
- Industry Biotechnology Research
- Website https://deepappletx.com/
- LinkedIn https://www.linkedin.com/company/deep-apple-therapeutics/about/
Mine Vision Systems | $12,500,000 | (Nov 5, 2025)
Planbase (YC S24) | $2,100,000 | (Nov 5, 2025)
The EVERY Company | $55,000,000 | (Nov 5, 2025)
Daylight Security | $33,000,000 | (Nov 5, 2025)
Azalea Therapeutics | $82,000,000 | (Nov 5, 2025)
Parable | $11,000,000 | (Nov 5, 2025)
Beacon Software | $250,000,000 | (Nov 5, 2025)
Sunflower Labs | $16,000,000 | (Nov 5, 2025)
C.Scale | $2,000,000 | (Nov 5, 2025)
Portal26 | $9,000,000 | (Nov 5, 2025)